Specialised commissioning contracting will begin in April 2014. We expect that clinical reference groups will provide input to area team medical directors in their specialised commissioning responsibilities.
While NHS England had previously decided that rituximab for SLE was not to be commissioned or funded, they recently
published a new policy within the National programmes of care and clinical reference groups section of their website.
The Interim Clinical Commissioning Policy Statement: Rituximab for the treatment of Systemic Lupus Erythematosus in adults - September 2013 Reference: NHS ENGLAND A13/PS/a (pdf) says rituximab will be funded, but only for use in specific situations, for refractory patients who continue to have active disease despite conventional therapy.
To secure the clinical evidence base to support decisions about the future funding of rituximab, we will need to show that we have complied with the policy, including submitting eligibility and outcome data to the BILAG biologics register, and with initial treatment decisions made at or with a centre commissioned to provide specialised care.
For more information,
please download Dr Peter Lanyon’s October 2013 letter to members (pdf).
Download the Commissioning Toolkit for Providers PDF from our